Eletriptan

CLINICAL USE

Acute relief of migraine

DOSE IN NORMAL RENAL FUNCTION

40–80 mg repeated after 2 hours if migraine recurs (do not take 2nd dose for the same attack)Maximum 80 mg in 24 hours

PHARMACOKINETICS

Molecular weight :463.4 (as hydrobromide)

%Protein binding :85

%Excreted unchanged in urine : 9

Volume of distribution (L/kg) :2–2.5

half-life – normal/ESRD (hrs) :4/Unchanged

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

30–50 20 mg; maximum daily dose 40 mg10–30 20 mg; maximum daily dose 40 mg, use with caution

<10 : 20 mg; maximum daily dose 40 mg, use with caution

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Unknown dialysability. Dose as in GFR <10 mL/min

HD :Unknown dialysability. Dose as in GFR <10 mL/min

HDF/high flux :Unknown dialysability. Dose as in GFR <10 mL/min

CAV/VVHD :Unknown dialysability. Dose as in GFR=10–30 mL/min

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

Antibacterials: concentration increased by clarithromycin and erythromycin – avoid concomitant use

Antidepressants: possibly increased serotonergic effects with duloxetine; increased serotonergic effects with St John’s wort – avoid concomitant use

Antifungals: concentration increased by itraconazole and ketoconazole – avoid concomitant use

Antivirals: concentration increased by indinavir, nelfinavir and ritonavir – avoid concomitant use

Ergot alkaloids: increased risk of vasospasm

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

OTHER INFORMATION

Non-renal clearance accounts for about 90% of the total clearanceManufacturer advises to avoid in severe renal impairment due to enhanced hypertensive effect.

See how to identify renal failure stages according to GFR calculation

See how to diagnose irreversible renal disease

Home